Cytori Therapeutics received Notification of Issuance from the United States Patent & Trademark Office for its core patent covering the Celution system (USPTO # 7,390,484). This patent protects Cytori's key device technology, which processes adult stem and regenerative cells from adipose tissue at the patient's bedside.
"Cytori pioneered the concept of a bedside device to deliver a patient's own adipose derived stem and regenerative cells in a single procedure," said Marc H. Hedrick, M.D., president of Cytori and named inventor on this patent. "We believe the broad claims in the '484 patent establish a strong barrier-to-entry against potentially competitive cell processing systems and reinforces our leadership position in regenerative medicine."
The new US patent is a central part of Cytori's global patent portfolio, which includes more than 150 pending patent applications and five new previously unannounced international patents. The new patents in Korea and Singapore cover Cytori's current Celution devices. Cytori was also granted patents in Korea and Australia related to the Company's StemSource Cell Bank. In South Africa, Cytori was granted a patent for using adipose derived stem and regenerative cells in cardiovascular cell therapy.
Celution 800 is currently being sold into the reconstructive surgery market and the Celution 900 system is being offered around the globe as part of the Company's StemSource Cell Bank. This patent also covers the Celution family of devices currently in co-development with Cytori's strategic partner, Olympus Corporation.
"The '484 patent is the key foundational patent within our intellectual property portfolio and offers Cytori long-term protection through at least 2024," said Christopher J. Calhoun, chief executive officer of Cytori. "Our patent portfolio works in concert with many other barriers-to-entry to protect all of our target markets for our first-in-class Celution system."
Cytori Therapeutics' goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells.